HBK Sorce Advisory LLC Raises Stock Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

HBK Sorce Advisory LLC grew its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 1.7% during the fourth quarter, HoldingsChannel.com reports. The fund owned 3,836 shares of the medical equipment provider’s stock after purchasing an additional 63 shares during the quarter. HBK Sorce Advisory LLC’s holdings in Intuitive Surgical were worth $2,002,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. Berbice Capital Management LLC acquired a new stake in Intuitive Surgical during the 4th quarter valued at $26,000. BankPlus Trust Department acquired a new stake in Intuitive Surgical during the 4th quarter valued at $28,000. Kohmann Bosshard Financial Services LLC acquired a new stake in Intuitive Surgical during the 4th quarter valued at $31,000. MidAtlantic Capital Management Inc. acquired a new stake in Intuitive Surgical during the 3rd quarter valued at $33,000. Finally, Decker Retirement Planning Inc. acquired a new stake in Intuitive Surgical during the 4th quarter valued at $36,000. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the stock. Royal Bank of Canada raised their price target on shares of Intuitive Surgical from $611.00 to $641.00 in a report on Monday, January 27th. Truist Financial raised their price target on shares of Intuitive Surgical from $640.00 to $666.00 and gave the company a “buy” rating in a report on Friday, January 24th. JPMorgan Chase & Co. raised their price target on shares of Intuitive Surgical from $575.00 to $675.00 and gave the company an “overweight” rating in a report on Friday, January 24th. Erste Group Bank raised shares of Intuitive Surgical from a “hold” rating to a “buy” rating in a report on Tuesday, November 19th. Finally, BTIG Research raised their price objective on shares of Intuitive Surgical from $535.00 to $561.00 and gave the stock a “buy” rating in a report on Tuesday, November 26th. One research analyst has rated the stock with a sell rating, four have given a hold rating and sixteen have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $613.10.

Insider Activity

In related news, EVP Brian Edward Miller sold 8,900 shares of Intuitive Surgical stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $485.07, for a total value of $4,317,123.00. Following the sale, the executive vice president now directly owns 5,758 shares in the company, valued at $2,793,033.06. This trade represents a 60.72 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Amal M. Johnson sold 4,635 shares of Intuitive Surgical stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $566.60, for a total transaction of $2,626,191.00. Following the completion of the sale, the director now owns 12,275 shares in the company, valued at approximately $6,955,015. This represents a 27.41 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 22,209 shares of company stock valued at $11,928,127. Company insiders own 0.90% of the company’s stock.

Intuitive Surgical Stock Performance

NASDAQ ISRG opened at $476.78 on Friday. Intuitive Surgical, Inc. has a one year low of $364.17 and a one year high of $616.00. The company has a 50-day simple moving average of $568.47 and a 200-day simple moving average of $531.22. The firm has a market capitalization of $169.82 billion, a PE ratio of 74.38, a price-to-earnings-growth ratio of 5.85 and a beta of 1.43.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.